Heron Therapeutics reports Q3 net product sales of $32.8M; narrows FY2024 guidance to positive Adj EBITDA

HERON THERAPEUTICS, INC. /DE/

2024-Q3 EPS reported -$0.11 revenue$103,504,000

Q3 acute care franchise net product sales $7.4M (+57% YoY); oncology franchise $25.4M (-5% YoY).
YTD Adjusted EBITDA positive at $1.4M; FY2024 Adj EBITDA guidance narrowed to $2M-$5M (from $(10)-$3M).
ZYNRELEF VAN approved Sep 24, on track for Q4 launch; CMS final rule includes ZYNRELEF for separate payment ($2,267.26 limit) through at least 2027.
Cash and equivalents $70.9M at Sep 30, 2024 vs $80.4M at Dec 31, 2023.
Total net product sales for first 9 months 2024: $103.5M vs $92.8M in prior year period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.